You are here
April 5, 2022
Antibodies recognize new SARS-CoV-2 Omicron variant after booster
At a Glance
- After a booster vaccination, levels of antibodies in the blood that could bind to and neutralize a new Omicron subvariant increased substantially.
- The quick spread of this new subvariant, called BA.2, is likely due to its greater infectiousness rather than its ability to evade the immune system.
Since scientists in South Africa announced its discovery in November 2021, the Omicron variant of SARS-CoV-2 has rapidly become dominant around the world. It currently accounts for almost all COVID-19 cases in the U.S.
Omicron has a large number of mutations in its spike protein. These make it better at latching onto and infecting cells. However, studies have shown that vaccines developed earlier in the pandemic produce an immune response that can recognize and block Omicron after a booster shot. This means that vaccines still help prevent serious illness from Omicron.
But SARS-CoV-2 continues to evolve. Three subvariants of Omicron have been identified to date. The one responsible for the surge in cases that began in late 2021 is called BA.1. Recently, the number of cases driven by a newer subvariant, called BA.2, has increased sharply. It hasn’t been known whether antibodies—produced either by vaccination or previous SARS-CoV-2 infection—can effectively recognize BA.2.
A research team led by Dr. Dan Barouch from Beth Israel Deaconess Medical Center examined neutralizing antibodies produced after vaccination or infection. These are antibodies that can bind to the virus and block its entry into cells.
The team tested antibodies from the blood of 24 people who had been vaccinated and boosted with the Pfizer-BioNTech shot. They also looked at antibodies from 8 people who had recovered from COVID-19, 7 of whom had also been vaccinated.
The study was funded in part by NIH’s National Cancer Institute (NCI). Results were published on March 16, 2022, in the New England Journal of Medicine.
As with the Omicron variant BA.1, the number of neutralizing antibodies in the blood after initial vaccination that could recognize BA.2 was more than 20 times lower than those that could identify the original virus. This number continued to decline six months after vaccination.
However, after the booster dose, levels of antibodies that could neutralize BA.2 jumped substantially. The number that could recognize BA.2—as well as BA.1—after the booster dose was higher than those recognizing the original virus after only the first two shots.
The number of antibodies that could recognize BA.2 were even higher in people who had been vaccinated and infected with the original Omicron variant. The one person who had no detectible neutralizing antibodies in their blood after exposure to SARS-CoV-2 hadn’t been vaccinated.
“These results indicate that the recent increase in COVID-19 cases caused by BA.2 is more likely due to an improved ability of the virus to spread from person to person rather than its ability to evade the immune system,” Barouch notes.
The results, combined with findings from other studies, show that a booster dose prompts the body to makes antibodies capable of neutralizing a range of SARS-CoV-2 variants.
—by Sharon Reynolds
- COVID-19 Immune Response Improves for Months after Vaccination
- COVID-19 Vaccines Induce Immune Response to Omicron
- Study Suggests COVID-19 Vaccines Do Not Reduce Fertility
- COVID-19 Vaccines Linked to Small Increase in Menstrual Cycle Length
- Measuring Protection after COVID-19 Vaccination
- Moderna COVID-19 Booster May Protect Against Variants
- Understanding SARS-CoV-2 Antibody Binding
- Moderna COVID-19 Vaccine Generates Long-Lasting Immune Memory
- Vaccines Prevented up to 140,000 COVID-19 Deaths in U.S.
- Coronavirus (COVID-19)
- COVID-19 (CDC)
References: Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. Yu J, Collier AY, Rowe M, Mardas F, Ventura JD, Wan H, Miller J, Powers O, Chung B, Siamatu M, Hachmann NP, Surve N, Nampanya F, Chandrashekar A, Barouch DH. N Engl J Med. 2022 Mar 16. doi: 10.1056/NEJMc2201849. Online ahead of print. PMID: 35294809.
Funding: NIH’s National Cancer Institute (NCI) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Massachusetts Consortium on Pathogen Readiness; Ragon Institute; Musk Foundation; Burroughs Wellcome Fund.